1304 ET - Johnson & Johnson's latest quarterly results offer a positive signal for medical device end markets, even though the company reported lower-than-expected growth in its medical device division, Baird analysts say in a note. J&J's medical technology miss was largely due to company-specific issues in its cardiovascular unit, masking reasonably solid performances from surgical, vision and orthopedics, they say. The analysts say the report offers positive read throughs for companies like Zimmer Biomet Holdings and Stryker in orthopedics, and for Medtronic and Abbott Laboratories in cardio and electrophysiology, among others. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

July 15, 2026 13:04 ET (17:04 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.